Lilly to Resubmit Application For Arthritis Drug

Posted: Updated:
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Delaware-based Incyte Corp. (Nasdaq: INCY) have announced plans to resubmit the New Drug Application for a once-daily treatment for rheumatoid arthritis. In April, the U.S. Food and Drug Administration rejected an NDA for baricitinib, saying more clinical results were needed.

Lilly says the resubmission package, which will be provided to the FDA before the end of January 2018, will include new safety and efficacy data. The companies expect the FDA to classify the application as a Class II resubmission, which means a new six-month review cycle will begin.

"We are committed to making life better for people living with RA. There is a significant unmet need for Americans suffering from this debilitating disease in spite of available therapies," said Christi Shaw, president of Lilly Bio-Medicines. "We are pleased with the opportunity to provide our resubmission package for baricitinib sooner than anticipated and look forward to continuing to work with the FDA as we seek to bring baricitinib to people with RA in the U.S."

Lilly and Incyte submitted the original NDA in January 2016. The following March, the companies published results from a Phase 3 global study in the New England Journal of Medicine, showing the drug met its primary endpoint.

In July, the Japan Ministry of Health, Labor and Welfare granted marketing approval for the drug, also known as Olumiant, based on four Phase 3 clinical trials.

  • Perspectives

    • Disagreeing Isn't Inherently Disagreeable

      Most of us have an inherent distaste for conflict. And somewhere along the way, society has reached a conclusion that disagreement is a bad thing. When it comes to business advice and decisions, that conclusion can be deadly. I see two factors that have contributed to the current state of disagreement. One is the national political climate, which is the most polarized I can remember since my father was snarling about those damned hippies. The other is social media, which seems to...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • KAR's Big Carmel Investment About Talent 'Fight'

      KAR Auction Services Inc. (NYSE: KAR) Chief Executive Officer Jim Hallett says a planned $80 million investment in a new Carmel headquarters will serve the company's existing needs and boost talent attraction. Some 900 employees are located at the company's current HQ, and KAR says the new space will house 400 new workers that will be added in the coming years. Hallett says "we're all in a fight for talent," especially in the technology space. He calls central Indiana...

    • INDOT Discusses Timeline For 'North Split' Overhaul

      One of the busiest interchanges in the state is going to be rebuilt. The Indiana Department of Transportation has announced the overhaul of the I-65/I-70 North Split in Indianapolis will include rehabilitation or widening of 32 bridges, adding new bridges and making room for future through-lane capacity on both interstates. The interchange handles some 170,000 cars per day. It was built 50 years ago and INDOT says its "useful life" is nearing the end.

    • GOP: Trump Set For Indiana Visit

      The Indiana Republican Party says President Donald Trump will make an appearance in Indiana next week. Specific details regarding the visit, including a location, have not yet been released. 

    • KAR Auction Services Plans $80M Carmel Expansion

      Carmel-based KAR Auction Services Inc. (NYSE: KAR) has announced a headquarters expansion that is expected to create 400 jobs by 2020. The company plans to invest $80 million into what it says will be a state-of-the-art campus to house 1,500 workers. During an announcement Tuesday at the Center for the Performing Arts, Chief Executive Officer Jim Hallett said...

    • Cook Creates 'Really Big Day in Bloomington'

      The president of Bloomington-based Cook Group Inc. says Tuesday's agreement to sell its Cook Pharmica LLC subsidiary to New Jersey-based Catalent Inc. (NYSE: CTLT) and the decision to acquire a former General Electric facility near the company's headquarters will have a positive impact on the city and state. Pete Yonkman says the nearly $1 billion dollar deal for Cook Pharmica has been six months in the making.